192 related articles for article (PubMed ID: 22975816)
21. Paralytic ileus following "subcutaneous bortezomib" therapy: focus on the clinical emergency-report of two cases.
Mele G; Coppi MR; Melpignano A; Quarta G
Clin Exp Med; 2016 Feb; 16(1):99-101. PubMed ID: 25600700
[TBL] [Abstract][Full Text] [Related]
22. Acute pancreatitis caused by bortezomib.
Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
[TBL] [Abstract][Full Text] [Related]
23. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
25. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
27. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
28. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
[TBL] [Abstract][Full Text] [Related]
29. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
30. [Aggravated post-herpetic neuralgia due to bortezomib].
Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
[TBL] [Abstract][Full Text] [Related]
31. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
[TBL] [Abstract][Full Text] [Related]
32. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
33. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Hsiao SC; Wang MC; Chang H; Pei SN
Ann Pharmacother; 2010 Mar; 44(3):587-9. PubMed ID: 20150504
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
35. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
37. Bortezomib.
Tariman JD; Lemoine C
Clin J Oncol Nurs; 2003; 7(6):687-9. PubMed ID: 14705489
[No Abstract] [Full Text] [Related]
38. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
39. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib-related diffuse alveolar hemorrhage.
Wirk B
J Clin Oncol; 2012 Dec; 30(36):e379-81. PubMed ID: 23150703
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
